Correlation of early metastatic response by 123I-metaiodobenzylguanidine scintigraphy with overall response and event-free survival in stage IV neuroblastoma - PubMed (original) (raw)
. 2003 Jul 1;21(13):2486-91.
doi: 10.1200/JCO.2003.09.122.
Affiliations
- PMID: 12829667
- DOI: 10.1200/JCO.2003.09.122
Correlation of early metastatic response by 123I-metaiodobenzylguanidine scintigraphy with overall response and event-free survival in stage IV neuroblastoma
Katherine K Matthay et al. J Clin Oncol. 2003.
Abstract
Purpose: Metaiodobenzylguanidine (MIBG), specifically taken up in cells of sympathetic origin, provides a highly sensitive and specific indicator for the detection of metastases in neuroblastoma. The aim of this study was to correlate early response to therapy by MIBG scan, using a semiquantitative scoring method, with the end induction response and event-free survival (EFS) rate in stage IV neuroblastoma.
Patients and methods: Seventy-five children older than 1 year and with stage IV neuroblastoma had 123I-MIBG scans at diagnosis, after two and four cycles of induction therapy, and before autologous stem-cell transplantation. The scans were read by two independent observers (concordance > 95%) using a semiquantitative method. Absolute and relative (score divided by initial score) MIBG scores were then correlated with overall pretransplantation response, bone marrow response, and EFS.
Results: The pretransplantation response rate was 81%, and the 3-year EFS rate was 32%, similar to a concomitant group of 375 stage IV patients. The median relative MIBG scores after two, four, and six cycles were 0.5, 0.24, and 0.12, respectively. The probability of having a complete response or very good partial response before transplantation was significantly higher if the relative score after two cycles was < or = 0.5, or, if after four cycles, the relative score was < or = 0.24. Patients with a relative score of < or = 0.5 after two cycles or a score of < or = 0.24 after four cycles had an improved EFS rate (P =.053 and.045, respectively).
Conclusion: Semiquantitative MIBG score early in therapy provides valuable prognostic information for overall response and EFS, which may be useful in tailoring treatment.
Similar articles
- Iodine-123 metaiodobenzylguanidine scintigraphy scoring allows prediction of outcome in patients with stage 4 neuroblastoma: results of the Cologne interscore comparison study.
Decarolis B, Schneider C, Hero B, Simon T, Volland R, Roels F, Dietlein M, Berthold F, Schmidt M. Decarolis B, et al. J Clin Oncol. 2013 Mar 1;31(7):944-51. doi: 10.1200/JCO.2012.45.8794. Epub 2013 Jan 22. J Clin Oncol. 2013. PMID: 23341514 - Scintigraphic response by 123I-metaiodobenzylguanidine scan correlates with event-free survival in high-risk neuroblastoma.
Katzenstein HM, Cohn SL, Shore RM, Bardo DM, Haut PR, Olszewski M, Schmoldt J, Liu D, Rademaker AW, Kletzel M. Katzenstein HM, et al. J Clin Oncol. 2004 Oct 1;22(19):3909-15. doi: 10.1200/JCO.2004.07.144. J Clin Oncol. 2004. PMID: 15459212 Clinical Trial. - The prognostic impact of functional imaging with (123)I-mIBG in patients with stage 4 neuroblastoma >1 year of age on a high-risk treatment protocol: results of the German Neuroblastoma Trial NB97.
Schmidt M, Simon T, Hero B, Schicha H, Berthold F. Schmidt M, et al. Eur J Cancer. 2008 Jul;44(11):1552-8. doi: 10.1016/j.ejca.2008.03.013. Epub 2008 Apr 16. Eur J Cancer. 2008. PMID: 18424129 Clinical Trial. - MIBG scintigraphy for the diagnosis and follow-up of children with neuroblastoma.
Boubaker A, Bischof Delaloye A. Boubaker A, et al. Q J Nucl Med Mol Imaging. 2008 Dec;52(4):388-402. Q J Nucl Med Mol Imaging. 2008. PMID: 19088693 Review.
Cited by
- An Open Annotated Dataset and Baseline Machine Learning Model for Segmentation of Vertebrae with Metastatic Bone Lesions from CT.
Haouchine N, Hackney DB, Pieper SD, Wells WM 3rd, Sanhinova M, Balboni TA, Spektor A, Huynh MA, Kozono DE, Doyle P, Alkalay RN. Haouchine N, et al. medRxiv [Preprint]. 2024 Oct 15:2024.10.14.24314447. doi: 10.1101/2024.10.14.24314447. medRxiv. 2024. PMID: 39484265 Free PMC article. Preprint. - The prognostic role of 18F-FDG PET/CT-based response evaluation in children with stage 4 neuroblastoma.
Lu X, Li C, Wang S, Yin Y, Fu H, Wang H, Cheng W, Chen S. Lu X, et al. Eur Radiol. 2024 Nov;34(11):7125-7135. doi: 10.1007/s00330-024-10781-w. Epub 2024 May 17. Eur Radiol. 2024. PMID: 38758254 - Management of High-Risk Neuroblastoma with Soft-Tissue-Only Disease in the Era of Anti-GD2 Immunotherapy.
Gorostegui M, Muñoz JP, Perez-Jaume S, Simao-Rafael M, Larrosa C, Garraus M, Salvador N, Lavarino C, Krauel L, Mañe S, Castañeda A, Mora J. Gorostegui M, et al. Cancers (Basel). 2024 Apr 29;16(9):1735. doi: 10.3390/cancers16091735. Cancers (Basel). 2024. PMID: 38730688 Free PMC article. - Predicting event-free survival after induction of remission in high-risk pediatric neuroblastoma: combining 123I-MIBG SPECT-CT radiomics and clinical factors.
Feng L, Yang X, Wang C, Zhang H, Wang W, Yang J. Feng L, et al. Pediatr Radiol. 2024 May;54(5):805-819. doi: 10.1007/s00247-024-05901-z. Epub 2024 Mar 16. Pediatr Radiol. 2024. PMID: 38492045 - Early Salvage Chemo-Immunotherapy with Irinotecan, Temozolomide and Naxitamab Plus GM-CSF (HITS) for Patients with Primary Refractory High-Risk Neuroblastoma Provide the Best Chance for Long-Term Outcomes.
Muñoz JP, Larrosa C, Chamorro S, Perez-Jaume S, Simao M, Sanchez-Sierra N, Varo A, Gorostegui M, Castañeda A, Garraus M, Lopez-Miralles S, Mora J. Muñoz JP, et al. Cancers (Basel). 2023 Oct 3;15(19):4837. doi: 10.3390/cancers15194837. Cancers (Basel). 2023. PMID: 37835531 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical